      Document 0006
 DOCN  DRG0006
 UNIQUE IDENTIFIER        DRG-0241
 NAME OF SUBSTANCE        HBY 097 [FDA 252A]
 STANDARD CHEMICAL NAME   (S)-3,4-dihydro-7-methoxy-2(methylthio)-methy-
                          l-3-thioxo-1(2 H)-quinoxalinecarboxylic
                          acid-1-methylethylester [FDA 252A]
 SYNONYMS                 HBY-097 [MeSH]
 PROTOCOL ID NUMBERS      FDA 252A
 SECONDARY SOURCE ID      DRG
 PHARMACOLOGICAL ACTION   MODE OF ACTION: Non-nucleoside reverse
                          transcriptase inhibitor specific for HIV-1.
                          [FDA 252A]
 DISEASES STUDIED/TREATED Primary HIV infection [FDA 252A]
 CLASSIFICATION CODE      Antiretroviral [Natl Conf Hum Retroviruses
                          Relat Infect (2nd) 1995]
 CHEMICAL/PHYSICAL DATA   DRUG DESCRIPTION: Quinoxaline derivative
                          [Natl Conf Hum Retroviruses Relat Infect
                          (2nd) 1995]
 SUBSTANCE DELIVERY DATA  DOSAGE FORM: 250 mg tablets. [ FDA 252A]
 SUBSTANCE DELIVERY DATA  MODE OF DELIVERY: Oral. [FDA 252A]
 MANUFACTURERS            Hoechst-Roussel Pharmaceuticals Inc
 REFERENCES               Kleim JP, Rosner M, Winkler I, Paessens A,
                          Kirsch R, Hsiou Y, Arnold E, Riess G.
                          Selective pressure of a quinoxaline
                          nonnucleoside inhibitor of human
                          immunodeficiency virus type 1 (HIV-1) reverse
                          transcriptase (RT) on HIV-1 replication
                          results in the emergence of nucleoside
                          RT-inhibitor-specific (RT Leu-74-->Val or Ile
                          and Val-75-->Leu or Ile) HIV-1 mutants. Proc
                          Natl Acad Sci USA. 1996 Jan 9;93(1):34-8.
 REFERENCES               Kleim JP, Paessens A, Bender R, Kirsch R,
                          Meichsner C, Rosner M, Winkler I, Riess G.
                          Evaluation of in vitro resistance development
                          against the quinoxaline HBY 097 reveals novel
                          patterns of mutations within the HIV-1 gene
                          encoding the reverse transcriptase. Natl Conf
                          Hum Retroviruses Relat Infect (2nd). 1995 Jan
                          29-Feb 2:141.
 REFERENCES               Paessens A, Blunck M, Kleim JP, Meichsner C,
                          Riess G, Rosner M, Rubsamen HW, Winkler I.
                          HBY 097, in vitro antiviral profile against
                          HIV-1 in acute and persistent infection
                          systems: combined drug interaction with
                          different inhibitors of HIV-1 or other
                          viruses. Natl Conf Hum Retroviruses Relat
                          Infect (2nd). 1995 Jan 29-Feb 2:70.
 REFERENCES               Rosner M, Bender R, Billhardt UM, Dienst K,
                          Kirsch R, Kleim JP, Meichsner C, Paessens A,
                          Riess G, Winkler I. HBY 097, a new
                          quinoxaline derivative with highly potent and
                          selective anti-HIV-1 activity. Natl Conf Hum
                          Retroviruses Relat Infect (2nd). 1995 Jan
                          29-Feb 2:70.
 ENTRY MONTH              9511
 LAST REVISION DATE       960424
 

SOURCE: National Library of Medicine, Bethesda, MD.  Distributed by AEGIS.
